Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral formulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherenc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Patient Prefer Adherence
Main Authors: Tchobaniouk, Lesia V, McAllister, Erin E, Bishop, Danielle L, Carpentier, Rachel M, Heins, Katharine R, Haight, Robert J, Bishop, Jeffrey R
Formato: Artigo
Idioma:Inglês
Publicado: Dove 2019
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053417/
https://ncbi.nlm.nih.gov/pubmed/32184570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S192418
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares